Keros Therapeutics, Inc.
Every calculator, already run for KROS
Open the full toolkit →You have the numbers on KROS. Get the argument.
A written report on which of these readings actually decide the outcome for Keros Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering KROSAnalyst Price Target Disagreement for Keros Therapeutics, Inc.
Wall Street's bull case implies +126% from the current price; the bear case implies +44%. A 81% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for KROS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The comp…
KROS — frequently asked
Is KROS a buy right now?
Wall Street's consensus rating on Keros Therapeutics, Inc. is none across 7 analysts, with a mean price target of $19.83 (+79% vs. the current $11.08). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is KROS's next earnings date?
Keros Therapeutics, Inc. is next scheduled to report earnings around Nov 4, 2026. A full KROS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Keros Therapeutics, Inc.?
Analysts covering Keros Therapeutics, Inc. (KROS) range from a bear-case target of $16.00 to a bull-case high of $25.00, with a mean consensus target of $19.83 across 6 analysts. The spread of $9.00 (81% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Keros Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Keros Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KROS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Keros Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.